Navigation Links
YM BioSciences Closes Public Offering of Common Shares
Date:12/17/2010

r of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and an
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced today ... Officer, will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. ... the presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a ...
(Date:9/2/2014)... 2014 Culot brings life science ... management services  BioData, producer of Labguru, the ... announce the appointment of Louis Culot as ... VP Marketing and Business Development at BioDiscovery Inc., developer ... applications. Previously, Culot worked for 17 years ...
(Date:8/31/2014)... 31, 2014 Wockhardt Limited today announces a ... Anti-Infective research when two of its drugs, WCK 771 ... Product (QIDP) status from U.S. Food & Drug Administration ... against pathogens which have a high degree of unmet ... for Disease Control (a top U.S. government health and ...
(Date:8/29/2014)... Aug. 29, 2014  Pfenex Inc. (NYSE MKT: ... development of high-value and difficult to manufacture proteins ... and reported financial results for the second quarter ... successful completion of our initial public offering, we ... biosimilar product candidates, derived from our proprietary protein ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... AdvanceBio LLC, a Cincinnati-based advanced biofuel technology company, ... fuel ethanol process. The process is capable ... sugar beet and other similar crops as feedstock for ... generating zero liquid waste. When built in ...
... TIRAT CARMEL, Israel, August 31, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... Aug. 30 Marrone Bio Innovations (MBI) ... for the control of invasive mussels, at the ... San Diego, California, August 29 to September 2, 2010. ... representing academia, industry, government agencies, NGOs and other stakeholders ...
Cached Biology Technology:Zero Discharge Sweet Sorghum Ethanol Process Development 2InSightec Treats First Prostate Cancer Patients in Clinical Trials 2InSightec Treats First Prostate Cancer Patients in Clinical Trials 3InSightec Treats First Prostate Cancer Patients in Clinical Trials 4InSightec Treats First Prostate Cancer Patients in Clinical Trials 5InSightec Treats First Prostate Cancer Patients in Clinical Trials 6InSightec Treats First Prostate Cancer Patients in Clinical Trials 7InSightec Treats First Prostate Cancer Patients in Clinical Trials 8Marrone Bio Innovations to Present Invasive Mussel Control Solution 2
(Date:9/2/2014)... With their long, spiky legs and their propensity for ... stuff of nightmares. And now research from North Carolina ... spread into homes across the eastern United States. , ... or pose any kind of threat to humans," says ... State and lead author of a paper about the ...
(Date:9/1/2014)... An increasing amount of research shows an association between ... sedentary lifestyle. Now, a new Cornell University study points ... programs might lead people to eat twice as much ... an action movie while snacking your mouth will see ... on the new article just published in the ...
(Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Can action movies make you fat? 2Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... Who is related to whom, who begat whom, how did ... reptiles. In 2011, his fieldwork in Sri Lanka studying ... identity of 60 known species of snakes. With Sri Lankan ... amphibians and reptiles, and Dushantha Kandambi, a local naturalist and ...
... Copenhagen, Denmark, Shenzhen, China. Tue., 12 March 2013 ... world,s largest genomics organization, will be working together aiming ... genomics and bioinformatics capabilities of both institutions. This partnership ... food security, energy and health. , Prof Richard Cogdell, ...
... to have an ambiguous, obscure or hidden meaning. In ... are hidden inside their genes. Two University of ... tiny clams, long believed to be members of the ... along the rocky shores of southern Australia for millions ...
Cached Biology News:Sri Lankan snake study reveals new species, rich biodiversity in island country 2BGI and TGAC join efforts to tackle global challenges in food security, energy and health 2Cryptic clams: U-M biologists find species hiding in plain view 2Cryptic clams: U-M biologists find species hiding in plain view 3
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
...
...
Biology Products: